Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Amylyx Pharmaceuticals, Inc. (AMLX) Healthcare & Pipeline Overview

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapeutics for neurodegenerative diseases like ALS, positioning itself in a high-need, high-growth market. Its primary focus is AMX0035, a novel dual UPR-Bax apoptosis inhibitor, differentiating it from traditional treatment approaches.

What Is the Investment Thesis for AMLX?

The potential approval and commercial success of AMX0035 represent significant value drivers, addressing a critical unmet need in a market with limited treatment options. Key catalysts include ongoing clinical trials and regulatory decisions regarding AMX0035's approval. The company's focus on neurodegenerative diseases and its novel therapeutic approach offer differentiation in a competitive landscape. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other emerging therapies. With a market capitalization of $1.20 billion and a beta of -0.30, Amylyx exhibits moderate market capitalization and relatively low volatility compared to the broader market. Successful commercialization of AMX0035 could drive substantial revenue growth, while failure to obtain regulatory approval would significantly impact the company's valuation.

Based on FMP financials and quantitative analysis

AMLX Key Highlights

Lead product candidate AMX0035 targets ALS, a disease with high unmet medical need.

• Focus on dual UPR-Bax apoptosis inhibition represents a novel therapeutic approach.
• Market capitalization of $1.20 billion reflects investor confidence in AMX0035's potential.
• Beta of -0.30 indicates lower volatility compared to the overall market.
• Clinical-stage company with potential for significant revenue growth upon successful commercialization of AMX0035.

Who Are AMLX's Competitors?

AMLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AMLX's Key Strengths?

Novel therapeutic approach targeting UPR and Bax pathways.

• Focus on a high-need therapeutic area (ALS).
• Experienced management team with expertise in drug development.
• Positive clinical trial results for AMX0035.

What Are AMLX's Weaknesses?

Reliance on a single product candidate (AMX0035).

• Limited commercialization experience.
• High research and development costs.
• Dependence on regulatory approvals.

What Could Drive AMLX Stock Higher?

Regulatory decision on AMX0035 approval for ALS treatment by the FDA.

• Enrollment and data readout from ongoing clinical trials of AMX0035 in ALS.
• Expansion of AMX0035 development into other neurodegenerative diseases.

What Are the Key Risks for AMLX?

Negative return on equity (-55.7%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for AMX0035.
• Regulatory rejection of AMX0035 approval.
• Competition from other emerging ALS therapies.
• Pricing pressures from payers and healthcare systems.

What Are the Growth Opportunities for AMLX?

• Expansion into Other Neurodegenerative Diseases: Amylyx can leverage the AMX0035 platform to target other neurodegenerative diseases beyond ALS, such as Alzheimer's and Parkinson's disease. The market for Alzheimer's treatments alone is projected to reach $12 billion by 2028. This expansion strategy could diversify the company's product pipeline and revenue streams, mitigating the risk associated with a single product focus. The timeline for this expansion depends on the results of ongoing and future clinical trials.
• Geographic Expansion: Amylyx has the opportunity to expand its market presence beyond the United States and into Europe and other regions. The European market for ALS treatments is estimated to be worth $500 million annually. Securing regulatory approvals and establishing commercialization partnerships in these regions could significantly increase the company's revenue potential. This expansion is contingent on regulatory approvals from EMA and other international bodies.
• Strategic Partnerships and Acquisitions: Amylyx can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of AMX0035 and other pipeline candidates. Collaborations can provide access to additional funding, expertise, and distribution channels. The timeline for such partnerships is dependent on the progress of clinical trials and the overall market environment.
• Development of Next-Generation Therapies: Amylyx can invest in the development of next-generation therapies targeting novel pathways involved in neurodegeneration. This could involve the discovery and development of new drug candidates or the optimization of existing therapies. The timeline for this development is long-term, requiring significant investment in research and development.
• Real-World Evidence Generation: Amylyx can focus on generating real-world evidence (RWE) to support the long-term efficacy and safety of AMX0035. RWE can be used to demonstrate the value of the treatment to payers and healthcare providers, potentially leading to increased market access and adoption. The timeline for RWE generation is ongoing, requiring continuous data collection and analysis.

What Are AMLX's Competitive Advantages?

• Proprietary drug AMX0035 with a novel mechanism of action.
• Focus on a specific therapeutic area (neurodegenerative diseases).
• Intellectual property protection for AMX0035 and other pipeline candidates.

What Does AMLX Do?

Founded in 2013 and headquartered in Cambridge, Massachusetts, Amylyx Pharmaceuticals, Inc. is dedicated to developing innovative treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's inception was driven by the need for more effective therapies for ALS, a progressive and fatal neurodegenerative disease. Amylyx's lead product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol), represents a novel approach by targeting both the endoplasmic reticulum (ER) stress and mitochondrial dysfunction pathways implicated in neuronal cell death. AMX0035 is designed as a dual UPR-Bax apoptosis inhibitor. The company is also exploring the potential of AMX0035 in other neurodegenerative conditions. Amylyx operates primarily in the United States, focusing on clinical development and regulatory approval processes. The company's strategy revolves around advancing AMX0035 through clinical trials, securing regulatory approvals, and establishing commercialization partnerships to bring the treatment to patients. With a relatively small team of 123 employees, Amylyx emphasizes a focused and agile approach to drug development.

What Products and Services Does AMLX Offer?

• Develop therapeutics for amyotrophic lateral sclerosis (ALS).
• Focus on neurodegenerative diseases.
• Develop AMX0035, a dual UPR-Bax apoptosis inhibitor.
• Conduct clinical trials to evaluate the safety and efficacy of AMX0035.
• Seek regulatory approvals for AMX0035 from FDA and other agencies.
• Explore the potential of AMX0035 in other neurodegenerative diseases.

How Does AMLX Make Money?

• Develop and commercialize therapeutics for neurodegenerative diseases.
• Generate revenue through the sale of approved drugs.
• Partner with pharmaceutical companies for development and commercialization.

What Industry Does AMLX Operate In?

Amylyx Pharmaceuticals operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for ALS treatments is driven by the increasing prevalence of the disease and the limited availability of effective therapies. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms developing novel treatments for neurodegenerative diseases. Amylyx's focus on a dual UPR-Bax apoptosis inhibition strategy differentiates it from competitors targeting other pathways involved in neurodegeneration. The biotechnology industry is subject to evolving regulatory standards and pricing pressures, which can impact market access and profitability.

Who Are AMLX's Key Customers?

• Patients with amyotrophic lateral sclerosis (ALS).
• Healthcare providers who treat ALS patients.
• Pharmaceutical companies that may partner with Amylyx.

Company Profile

Amylyx Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Joshua Cohen. AMLX has traded publicly since 2022.

How Amylyx Pharmaceuticals, Inc. Is Valued

Analyst price targets span from $42.00 to $57.00, with a consensus of $52.20. At the current price of $32.58, that implies approximately 60% upside potential. Relative to its peer group, AMLX's quantitative score of 69/100 is below the peer average of 86/100.

Return on equity for Amylyx Pharmaceuticals, Inc. stands at -55.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -51.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 17.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.7%, the inverse of the P/E and a quick read on earnings relative to price.

Amylyx Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 79.88 places it in the safe zone, indicating low near-term bankruptcy risk.

Amylyx Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 11.0% below estimates on average.

Wall Street analysts project Amylyx Pharmaceuticals, Inc. revenue of about $81K for fiscal 2026, with EPS near $-1.51. The estimate reflects 7 contributing analysts.

Over the past six months, Amylyx Pharmaceuticals, Inc. insiders filed 17 SEC Form 4 transactions — 4 sales and 13 purchases. On net that is roughly 283K shares acquired (about $1.3M) — insiders putting money in tends to read as conviction.

AMLX Financials

AMLX Latest News

AMLX Analyst Consensus

AMLX MoonshotScore

Latest Amylyx Pharmaceuticals, Inc. Analysis

AMLX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources